Mirabegron in overactive bladder patients: efficacy review and update on drug safety.
Overactive bladder is a common condition, which significantly affects people's quality of life. The use of anticholinergic medication has been the mainstay of managing overactive bladder when conservative measures are not enough. Many patients stop anticholinergic medication because of the side effects and more recently the concerns about the effect of an anticholinergic burden and the development of dementia have been studied. Activation of β3 adrenoceptors has been shown to relax the detrusor muscle and subsequently lead to the development of the first β3 adrenoceptor agonist. Mirabegron is the first drug in this class to be approved for the use in overactive bladder. It has been extensively studied in phase II and III trials and has significant improvement in key overactive bladder parameters when compared with placebo. The incidence of side effects such as constipation, hypertension and tachycardia were comparable to anticholinergic medication but there was significantly less dry mouth incidence in the mirabegron groups. Mirabegron has been shown to be used safely in combination with solifenacin and tamsulosin. Head-to-head studies comparing efficacy and safety of mirabegron with anticholinergic medication would further help in the management strategy for overactive bladder.
Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, UK.
Katherine
K
Warren
Bristol Urological Institute, Southmead Hospital, Bristol, UK.
Helena
H
Burden
Bristol Urological Institute, Southmead Hospital, Bristol, UK.
Paul
P
Abrams
anticholinergic; mirabegron; overactive bladder; β3 agonist
J Urol. 2013 Oct;190(4):1173-80
23458471
Int J Clin Pharmacol Ther. 2014 Aug;52(8):693-701
24755125
Pharmacol Ther. 2011 Jul;131(1):40-9
21510978
BJU Int. 2015 Jan;115(1):32-40
24602031
PLoS One. 2013 May 31;8(5):e64111
23741303
J Urol. 2013 Oct;190(4):1320-7
23727415
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
17049716
Int Urol Nephrol. 2013 Feb;45(1):53-60
23212147
BJU Int. 2014 Jun;113(6):951-60
24471907
Eur Urol. 2013 Feb;63(2):296-305
23195283
J Pharmacol Exp Ther. 2012 Jul;342(1):163-8
22511202
Eur Urol. 2015 Jan;67(1):11-4
25092537
BMC Urol. 2013 Sep 18;13:45
24047126
Age Ageing. 2015 Mar;44(2):219-25
25430550
Urology. 2013 Aug;82(2):313-20
23769122
Eur Urol. 2012 Nov;62(5):834-40
22695239
Eur Urol. 2014 Apr;65(4):755-65
24275310
Neurourol Urodyn. 2009;28(4):287
19350662
Eur Urol. 2016 Feb;69(2):311-23
26422675
Eur Urol. 2015 Mar;67(3):577-88
24612659
JAMA Intern Med. 2015 Mar;175(3):401-7
25621434
J Urol. 2015 Mar;193(3):921-6
25254938
J Urol. 2013 Apr;189(4):1388-95
23079373
Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):212-6
26169181
Arch Intern Med. 2009 Jul 27;169(14):1317-24
19636034
Eur Arch Psychiatry Clin Neurosci. 2010 Nov;260 Suppl 2:S111-5
20960005
Neurourol Urodyn. 2013 Nov;32(8):1116-22
23424164
Curr Med Res Opin. 2016;32(4):621-38
26828974
Eur Urol. 2013 Feb;63(2):283-95
23182126
BJU Int. 2015 Oct;116(4):612-22
25639296
BJU Int. 2012 Dec;110(11):1767-74
22409769
Arch Gen Psychiatry. 2003 Feb;60(2):198-203
12578438
Int Urogynecol J. 2013 Sep;24(9):1447-58
23471546
Ther Adv Urol. 2015 Aug;7(4):167-79
26445596